ArticleFrontiers in pharmacology2026
Anti-arthritic activities of cross-linked hyaluronic acid-dexamethasone hydrogel in a rat model of gouty arthritis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gouty arthritis (GA) is a type of inflammatory joint disease in which the deposition of monosodium urate (MSU) crystals inside the joints leads to severe inflammatory reactions, such as synovitis. Cross-linked hyaluronic acid hydrogel (cHA gel) has been shown to have a chondroprotective effect, while dexamethasone (Dex) is an anti-inflammatory drug; both have been used in clinical practice to a certain extent. This study was designed to compare the therapeutic effects of cHA gel pre-mixed with Dex (cHA-Dex gel) or without Dex (cHA gel alone) in a rat model of GA. Methods: In this study, 2-month-old male Sprague-Dawley (SD) rats were used. The GA model was established by intra-articular injection of a solution containing 40 mg/mL MSU crystals and 0.1 mg/mL lipopolysaccharide (LPS) dissolved in saline, and this procedure was repeated every 2 weeks. The rats were subsequently randomly allocated into four groups ( Results: The findings showed that the deposition of intra-articular MSU/LPS led to pathological changes, including inflammation and cartilage damage. Micro X-ray scans showed that the knee joint structure treated with cHA-Dex gel had a much better level of integrity than the MSU/LPS + saline and MSU/LPS + cHA gel groups. In the MSU/LPS + cHA-Dex gel group, Indian ink staining was less, and safranin O-fast green staining showed an increase in proteoglycan (PG) content and a decrease in the extent of cartilage damage. Histological quantitative analysis showed statistically significant differences in the relevant scores ( Conclusion: Altogether, the cHA gel combined with Dex demonstrated superior therapeutic outcomes in comparison to cHA gel alone in a rat model of GA. The presented work provides preclinical evidence for a localized cHA-Dex gel delivery strategy that may complement existing clinical treatments for GA, with further validation required for translational application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.